The US Food and Drug Administration has granted fast track designation to the investigation therapy STX-0712 for the treatment of patients with relapsed or refractory chronic myelomonocytic leukemia.
STX-0712 is a CyTAC™ (cytotoxicity targeting chimera) targeting the the CCR2 receptor, highly expressed on malignant monocytes and bone marrow blasts to selectively eliminate disease-driving cells, according to a press release by Solu Therapeutics, the manufacturer of the drug. The company is also exploring the potential of the therapy in other hematologic malignancies, including acute myeloid leukemia.
A phase 1 open-label study evaluating the drug as a monotherapy is currently ongoing, with initial clinical data planned for submission to a hematology conference later this year, according to the press release.
Leave feedback about this